Melanoma research hub

Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies

This study uses a special scan called a PET/CT with a medicine called zirconium Zr 89 crefmirlimab berdoxam. It’s for people with advanced melanoma, Merkel cell cancer, kidney cancer, or lung cancer. We want to see if this scan can help predict how well immunotherapy will work for their cancer.

Intensified Monitoring of PhArmacology of Cabozantinib as a tool for Toxicity management in patients with renal cell carcinoma

This study looks at how closely watching how much Cabozantinib medicine is in your body can help manage side effects for kidney cancer patients. The goal is to reduce treatment interruptions by improving how we deal with these side effects.

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

This study is looking at new ways to treat advanced kidney cancer that hasn't been treated before. It combines three medicines to see if they work better together than two, aiming to help people live longer and keep their cancer from growing.

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

This study for advanced kidney cancer compares a standard treatment, Sunitinib, with two new combinations: Lenvatinib plus Everolimus, or Lenvatinib plus Pembrolizumab. The aim is to see if either new combination can keep the cancer from growing for longer. It's in the final stage of testing.

Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer

This study is looking at different combinations of immunotherapy medicines given before surgery for kidney cancer. It aims to see if these treatments can shrink tumours and improve outcomes for people with clear cell renal cell carcinoma.

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

This study is testing a drug called alectinib for different types of cancer that have a special gene change called ALK. It's already used for some lung cancers, and now doctors want to see if it can help other cancers with the same change.

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

This study looks at new drug combinations for kidney cancer that has spread or can't be removed. It compares different immune-boosting medicines with a drug called axitinib to see how safe and effective they are.

Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 with Tislelizumab in Patients with Advanced Solid Tumors

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

A Phase 1b, Open-Label, Dose-Escalation Trial of the Safety of and Antigen-Specific Immune Responses Elicited by VB.10 NEO in Combination With Atezolizumab in Subjects with Locally Advanced and Metastatic Tumors

Neoadjuvant AXITINIB plus AVELUMAB for patients with localized RCC and a moderate to high risk of recurrence (N17JAV)

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors

Nivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial)

TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

This study looks at a drug called entrectinib for different types of advanced cancer. It focuses on cancers with specific genetic changes (NTRK, ROS1, or ALK gene fusions). Researchers want to see if entrectinib can help treat these cancers.

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

This study is testing new combinations of medicines (Nivolumab with Cabozantinib) against a standard treatment (Sunitinib) for kidney cancer that has spread. We want to see if the new combination is safer and works better for people who haven't had treatment before.

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

This study is testing a new combination of treatments, Intismeran autogene and Pembrolizumab, for kidney cancer. We want to see if this combination, given after surgery, can help stop the cancer from coming back for longer compared to Pembrolizumab alone.

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

This study looks at new drug combinations for kidney cancer (renal cell carcinoma) that has come back after previous treatment. It aims to find out if these combinations are safe and effective. It's for people aged 18-120 with this specific type of kidney cancer.

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

This study is testing two anti-cancer drugs, cabozantinib and atezolizumab, alone and together, for various advanced cancers. It aims to find a safe combination dose and see how well it works and any side effects.

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Renal Adjuvant MultiPle Arm Randomised Trial

This study looks at new treatments for kidney cancer (renal cell carcinoma) after surgery. It compares two drugs, durvalumab and tremelimumab, given alone or together, against standard monitoring. The aim is to see if these drugs can stop the cancer from coming back or help people live longer.

Partial Volume High-Dose Irradiation in Renal Cell Carcinoma for Intra-TUmoural Control ALongside Current Management

This study looks at a new way to give radiotherapy for kidney cancer, both when it's just in one place or has spread. It compares the usual treatment to a shorter, more intense course to see if it's safe and practical.